Developing treatments for female sexual dysfunction

Clinical Pharmacology and Therapeutics

Volumn 89, Issue 1, 2011, Pages 137-141

  Jordan, R ^a   Hallam, T J ^a   Molinoff, P ^b   Spana, C ^a  

^a Palatin Technologies   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANDROGEN RECEPTOR AGONIST; BREMELANOTIDE; FLIBANSERIN; HORMONE RECEPTOR STIMULATING AGENT; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTAGLANDIN E1; SILDENAFIL; TESTOSTERONE; TIBOLONE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; COMORBIDITY; DEMOGRAPHY; DISEASE CLASSIFICATION; DRUG MECHANISM; DRUG SAFETY; ERECTILE DYSFUNCTION; FEMALE; FEMALE SEXUAL DYSFUNCTION; HORMONE SUBSTITUTION; HUMAN; HYPOACTIVE SEXUAL DESIRE DISORDER; MENOPAUSAL SYNDROME; NYMPHOMANIA; ORGASM DISORDER; OSTEOPOROSIS; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; SEXUAL AROUSAL; SEXUAL AROUSAL DISORDER; SEXUAL BEHAVIOR; TREATMENT DURATION;

ADULT; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUGS, INVESTIGATIONAL; ENDPOINT DETERMINATION; FEMALE; HUMANS; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL;

EID: 78650459686     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.262     Document Type: Article

References (23)

1. Basson, R. et al. Report of the international consensus development conference on female sexual dysfunction: defnitions and classifcations. J. Urol. 163, 888-893 (2000).
2. American Psychiatric association. Diagnostic and Statistical Manual of Mental Disorders 4th edn., Text revision. (american Psychiatric Publishing, Washington, DC (2000).
3. Frank, J.E., Mistretta, P. & Will, J. Diagnosis and treatment of female sexual dysfunction. Am. Fam. Physician 77, 635-642 (2008).
4. Laumann, E.O., Paik, A. & Rosen, R.C. Sexual dysfunction in the United States: prevalence and predictors. JAMA 281, 537-544 (1999). (Pubitemid 29081307)
5. Shifren, J.L., Monz, B.U., Russo, P.A., Segreti, A. & johannes, C.B. Sexual problems and distress in United States women: prevalence and correlates. Obstet. Gynecol. 112, 970-978 (2008).
6. Basson, R. Female sexual response: the role of drugs in the management of sexual dysfunction. Obstet. Gynecol. 98, 350-353 (2001).
7. Basson, R. Pharmacotherapy for women's sexual dysfunction. Expert Opin. Pharmacother. 10, 1631-1648 (2009).
8. US Food and Drug administration. Intrinsa® Briefng Document FDa advisory Committee for Reproductive Health Drugs meeting, http://www.Fda.Gov/ ohrms/dockets/ac/04/briefng/2004-4082b1.Htm2 December 2004.
9. US Food and Drug administration. FDa Minutes from Intrinsa® advisory Committee for Reproductive Health Drugs meeting, http://www.Fda.Gov/ohrms/ dockets/ac/04/transcripts/2004-4082T1.htm2 December 2004.
10. ClinicalTrials.Gov. Safety and Efcacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women (BLOOM) .http://clinicaltrials.Gov/ct2/show/NCT00657501?term=libigel&rank=27. (2010).
11. US Food and Drug administration. FDa Briefng Document, Flibanserin advisory Panel. http://www.Fda.Gov/advisoryCommittees/ CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsadvisoryCommittee/ ucm215436.htm. (2010).
12. US Food and Drug administration. FDa Flibanserin advisory Panel meeting webcast, 18 june 2010.
13. Levine, S., Brown, C., Palace, E., Fischkof, S. & Schnorrbusch, C. Phase 2B bremelanotide study in pre-and post menopausal women with female sexual arousal disorder. American College of Obstetricians and Gynecologists 56th annual Clinical Meeting, New Orleans, La, 3-7 May 2008.
14. Segraves, R.T., Clayton, A., Croft, H., Wolf, A. & Warnock, J. Bupropion sustained release for the treatment of hypoactive sexual desire disorder in premenopausal women. J. Clin. Psychopharmacol. 24, 339-342 (2004).
15. Segraves, R.T. et al. Bupropion sustained release (SR) for the treatment of hypoactive sexual desire disorder (HSDD) in nondepressed women. J. Sex Marital Ther. 27, 303-316 (2001).
16. US Food and Drug administration. Center for Drug Evaluation and Research. 2000 Draft Guidance for Industry-Female Sexual Dysfunction: Clinical Development of Drug Products for Treatment. (May 2000).
17. Shames, D., Monroe, S.E., Davis, D. & Soule, L. Regulatory perspective on clinical trials and end points for female sexual dysfunction, In particular, Hypoactive sexual desire disorder: formulating recommendations in an environment of evolving clinical science. Int. J. Impot. Res. 19, 30-36 (2007).
18. Basson, R. Women's sexual dysfunction: revised and expanded defnitions. CMAJ 172, 1327-1333 (2005).
19. Althof, S.E., Rosen, R.C., DeRogatis, L., Corty, E., Quirk, F. & Symonds, T. Outcome measurement in female sexual dysfunction clinical trials: review and recommendations. J. Sex Marital Ther. 31, 153-166 (2005).
20. Nijland, E., Davis, S., Laan, E. & Schultz, W.W. Female sexual satisfaction and pharmaceutical intervention: a critical review of the drug intervention studies in female sexual dysfunction. J. Sex. Med. 3, 763-777 (2006).
21. Derogatis, L., Clayton, A., Lewis-D'agostino, D., Wunderlich, G. & Fu, Y. Validation of the female sexual distress scale-revised for assessing distress in women with hypoactive sexual desire disorder. J. Sex. Med. 5, 357-364 (2008).
22. Althof, S.E., Dean, J., Derogatis, L.R., Rosen, R.C. & Sisson, M. Current perspectives on the clinical assessment and diagnosis of female sexual dysfunction and clinical studies of potential therapies: a statement of concern. J. Sex. Med. 2 (suppl.3), 146-153 (2005).
23. Flibanserin Phase III trial data. 12th Congress of the European Society for Sexual Medicine, Lyon, France, November 2009.